Anti-Outer membrane protein C antibodies in colorectal neoplasia

. 2016 Jul ; 61 (4) : 295-9. [epub] 20151126

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid26612659
Odkazy

PubMed 26612659
DOI 10.1007/s12223-015-0437-4
PII: 10.1007/s12223-015-0437-4
Knihovny.cz E-zdroje

Sporadic colorectal cancer (CRC) represents an enormous problem worldwide. Large intestinal microbiota play an important role in the colorectal carcinogenesis. The aim of the study was to investigate anti-Outer membrane protein C (anti-OmpC) antibodies, aimed at porin C, which is embedded in the outer membrane of gram-negative bacteria, in patients with colorectal adenoma (CRA), CRC and controls. The study included 22 patients with CRA (11 men, 11 women, aged 26-79, mean 65 ± 12), 11 patients with CRC (9 men, 2 women, aged 50-83, mean 66 ± 11) and 45 controls, blood donors (24 men, 21 women, aged 20-58, mean 38 ± 10). Serum anti-OmpC antibodies were investigated by means of ELISA. Values of 0-20 U/mL were considered to be negative; values >25 U/mL were assessed as positive. A total of 9/11 (82 %) patients with CRC had positive anti-OmpC antibodies. Anti-OmpC antibodies were negative or grey-zone in 37/45 (82 %) controls. Serum anti-OmpC were found to be significantly higher in patients with CRC (median 42.4, interquartile range (IQR) 22.2) compared to controls (median 18.3, IQR 12.4), p < 0.001. No statistically significant difference in anti-OmpC was found between controls (median 18.3, IQR 12.4) and CRA patients (median 17.7, IQR 16.5), p = 0.326. Anti-OmpC were significantly higher in patients with CRC (median 42.4, IQR 22.2) compared to patients with CRA (median 17.7, IQR 16.5), p = 0.011. Positivity of anti-OmpC antibodies was found in patients with CRC, which supports the contribution of gram-negative large intestinal microbiota to the pathogenesis of CRC.

Zobrazit více v PubMed

Int J Cancer. 2015 Mar 1;136(5):E359-86 PubMed

Future Microbiol. 2013 Apr;8(4):445-60 PubMed

Microbiol Mol Biol Rev. 2003 Dec;67(4):593-656 PubMed

EMBO Rep. 2006 Jul;7(7):688-93 PubMed

PLoS One. 2011;6(5):e20447 PubMed

J Microbiol Methods. 2008 Feb;72(2):124-32 PubMed

BMC Infect Dis. 2014 Dec 24;14:733 PubMed

J Biol Chem. 1994 Feb 11;269(6):3905-8 PubMed

J Lipid Res. 2006 Feb;47(2):241-59 PubMed

BMC Gastroenterol. 2014 Dec 31;14:190 PubMed

Dig Dis. 2009;27(3):206-11 PubMed

Microb Pathog. 2012 Sep;53(3-4):180-2 PubMed

Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):323-36 PubMed

Tumour Biol. 2013 Jun;34(3):1285-300 PubMed

Gastroenterology. 2004 Feb;126(2):414-24 PubMed

Cancer Res. 1975 Nov;35(11 Pt. 2):3421-6 PubMed

J Biol Chem. 1976 Apr 10;251(7):2176-8 PubMed

Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11537-42 PubMed

Mol Microbiol. 2000 Jul;37(2):239-53 PubMed

Science. 2006 Aug 11;313(5788):848-51 PubMed

Infect Immun. 2000 Mar;68(3):1542-8 PubMed

Infect Immun. 2012 May;80(5):1815-22 PubMed

Am J Gastroenterol. 2004 Nov;99(11):2235-41 PubMed

Infect Immun. 2009 Nov;77(11):4696-703 PubMed

Carcinogenesis. 2007 Nov;28(11):2419-25 PubMed

Am J Gastroenterol. 2008 Mar;103(3):665-81 PubMed

Nutr Cancer. 2012;64(1):34-40 PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...